Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Most cancers Institute; affiliate professor, medication, Harvard Medical Faculty, discusses findings...
The combination of brokers resembling antibody-drug conjugates (ADCs) and immunotherapies into the breast most cancers therapy paradigm has underscored the necessity to perceive...
